Case Study: A First-In-Class Peptide Drug Conjugate (PDC) Platform Targeting Sortilin (SORT1) Receptor Positive Cancers
Time: 11:00 am
day: Pre-Conference Seminar Day - Track C
Details:
- Understanding why the normal function of a scavenger receptor, SORT1, can be exploited to rapidly transport novel peptide drug conjugates (PDCs) into cancer cells
- Discussing the over expression of SORT1 in many solid tumours
- Learn about Thera’s lead PDC candidate, TH1902, across multiple solid tumours
- Review the potential of this novel SORT1+ platform for future developments